Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN51,9752,01-0,57
Msft-6,05
Nokia4,18454,3595-1,73
IBM0,89
Mercedes-Benz Group AG55,8755,89-1,24
PFE-0,77
01.11.2024 0:28:52
Indexy online
AD Index online
select
AD Index online
 

  • 31.10.2024 17:31:30
Addex Pharmaceut (ADXN.S, Swiss Exchange)
Poslední obchod Změna (%) Změna (CHF) Objem obchodů (CHF)
0,0794 2,85 0,00 25 516
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.11.2024
Popis společnosti
Obecné informace
Název společnostiAddex Therapeutics Ltd
TickerADXN
Kmenové akcie:Ordinary Shares
RICADXN.S
ISINCH0029850754
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.12.2023 23
Akcie v oběhu k 30.06.2024 98 297 751
MěnaCHF
Kontaktní informace
UliceChemin des Mines, 9
MěstoPLAN-LES-OUATES
PSČ1202
ZeměSwitzerland
Kontatní osoba 
Funkce kontaktní osoby 
Telefon41 228 841 555
Fax41228841556

Business Summary: Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Addex Therapeutics Ltd revenues decreased 69% to SF350K. Net loss before extraordinary items decreased 28% to SF2.2M. Revenues reflect discovery, development and commercialization segment decrease of 45% to SF350K. Lower net loss reflects discovery, development and commercialization segment loss decrease of 34% to SF1.7M.
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICSMedical Laboratories
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Medical Laboratories
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
NAICS1997Medical Laboratories
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries
SICMedical Laboratories



  • Poslední aktualizace: 01.11.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Co-Founder, Member of the Executive Management, DirectorTim Dyer56
Member of the Executive Management, Head of Translational ScienceMikhail Kalinichev5701.01.2021
Member of the Executive Management, Head of Discovery - BiologyRobert Luetjens5601.01.2002